Portfoliotracker

Vor Biopharma Inc.

VOR · NASDAQGS · Healthcare Biotechnology 15/100 E

18,97 $
▼ −0,45 (−2,32 %)
Pre-market delayed by 15 min
Price as of 16. 11. 22:00, fetched 17. 11. 12:00
Next earnings–
Ex-dividend–
Analysts–
50 / 200 day average– / –

Price

Portfoliotracker score15 / 100 Market cap1,13 mld. $ P/E0,1 Forward P/E-5,9 P/S– P/B– EV/EBITDA– Dividend yield– FCF yield-10,57 % EPS300,56 $ Net margin0,0 % Return on equity– Beta1,83 Debt / equity–
52-week range 6,50 to 26,00
3-month average volume0,9 M

Finance

Where the revenue goes

Loading the income statement flow…

Fundamentals

Loading key figures…

Insiders, analysts and people

All trades and changes

Loading insiders, analysts and opinions…

Co se právě děje

AI souhrn
Objednat AI souhrn, co se u firmy právě děje Vytvoří se jednou na pozadí a pak ho uvidí všichni. Ve verzi Free 3 objednávky měsíčně.

About the company

Vor Biopharma Inc., a clinical-stage biopharmaceutical company, focuses on the development of a novel therapy in the treatment of autoimmune diseases. The company offers telitacicept, a novel fusion protein for the treatment of generalized myasthenia gravis, systemic lupus erythematosus, and rheumatoid arthritis, as well as Sjögren's disease and IgA nephrapathy. It has a license agreement with RemeGen Co., Ltd. for the exploitation, development, and commercialization of telitacicpet and related products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Website
vorbio.com
Employees
76
Country
United States
Fiscal year end
31. 12.
Data since
5. 2. 2021

Explore further

Similar companies IMCRCGEMDSGNSANA

Intraday chart

Your own portfolio, properties and finances in one place.

The account is free with no time limit. Only you see your data; nobody adds it up with others.

This is saved to your account. You can keep browsing, calculating and comparing without signing in.

Welcome back

Sign in and pick up where you left off.

or continue with

No account yet? Create a free account